Modality
mRNA
MOA
KRASG12Di
Target
GLP-1R
Pathway
Innate Imm
Prostate CaMCL
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
~Sep 2021
→ ~Dec 2022
Phase 2
Mar 2023
→ Mar 2026
Phase 2Current
NCT04492741
2,688 pts·Prostate Ca
2023-03→TBD·Active
NCT07916243
2,558 pts·Prostate Ca
2025-09→2026-03·Not yet recruiting
5,246 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-011mo agoPh3 Readout· Prostate Ca
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2/3
Active
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-03-01 · 1mo ago
Prostate Ca
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04492741 | Phase 2/3 | Prostate Ca | Active | 2688 | PFS |
| NCT07916243 | Phase 2/3 | Prostate Ca | Not yet recr... | 2558 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R |